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ABSTRACT 
  
Objective: The objective of this systematic review is to determine how well leukotriene 
inhibitors/modifiers reduce symptoms associated with nasal polyps. 
  
Study Design: The studies included in this review are three randomized controlled trials.  
  
Data Source: The three RCTs in this review were obtained by performing a PubMed search using 
the keywords “nasal polyp”, “leukotriene”, and “Montelukast”. All articles were published in 
English and in peer-reviewed journals.   
  
Outcomes Measured: The three studies determine whether there was significant improvement of 
symptoms in patients with nasal polyps who were treated adjunctively with leukotriene 
inhibitors/modifiers. The symptoms were measured before and after the treatments using three 
different symptom score guidelines.  
  
Results: Patients who were diagnosed with chronic rhinosinusitis with nasal polyposis who were 
given Montelukast (leukotriene inhibitor) as adjunctive therapy demonstrated statistically 
significant reduction in symptoms, p<0.05. In all three studies, Wu et al10, Yelverton et al11, Suri 
et al12 the symptom scores decreased significantly in comparison to patients who received no 
Montelukast adjunctive therapy.  
  
Conclusions: Based on the systematic review of the three randomized controlled trials, one can 
decisively say that leukotriene inhibitors/modifiers (Montelukast) can reduce the symptoms 
associated with the presence of nasal polyps. All three studies verified statistically significant 
reduction in symptoms compared to the control groups.  
  
Key Words: Leukotriene, Nasal Polyps, Montelukast 
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INTRODUCTION  
Nasal polyps are noncancerous growths inside the nose or sinuses which can cause or 
exacerbate a variety of symptoms.1 Their development can be linked to chronic inflammation, 
autonomic nervous system dysfunction, and genetic predisposition.1 However, a definitive 
pathogenesis of these polyps has yet to be discovered.1 Theories state that nasal polyps arise 
from conditions leading to chronic inflammation of the nasal mucosa such as allergic states or 
recurrent infection.1 The nasal polyps most commonly discussed are benign semitransparent 
lesions which arise from the mucosa of the nasal cavity or from the paranasal sinuses.1 They are 
usually found at the outflow tract of the sinuses and can result in symptoms such as rhinorrhea, 
congestion, postnasal drip, anosmia, facial pain or headache, or snoring.1 Children with chronic 
sinusitis, cystic fibrosis, allergic rhinitis, and allergic fungal sinusitis are more likely to have 
multiple nasal polyps. 1  
 Nasal polyps are relevant to the physician assistant practice because they affect 1-4% of 
adults and 0.1% of children in the United States.1 Patients affected with the symptoms of nasal 
polyps will first present to a primary care practice, a field containing a large portion of all 
physician assistants.1 They have increased occurrence in men and usually manifest after 20 years 
of age, if they are benign.1 The incidence of cystic fibrosis patients with nasal polyps ranges 
between 6-48%.1 The polyps obstruct the outflow tract of the sinuses leading to recurrent sinus 
infections or allergic rhinitis.1 Nasal polyps are relevant to patients because those affected will 
have multiple doctor appointments and days of work/school missed a year.1 
 Nasal polyps themselves do not require treatment.2 The infections which result because 
of their obstruction is what costs the most.2 It is estimated that sinusitis costs the U.S. $6 billion 
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every year to treat.2 Therefore if 1-4% of the population has nasal polyps, recurrent sinusitis 
treatment could cost over $240 million a year.2 Patients with nasal polyps will have recurrent 
sinusitis which ends up costing them even more.2 Recurrent outpatient visits lead to 
accumulation of various medications and antibiotics which, without health insurance, can 
become costly.1 Once the decision is made to remove the nasal polyps through endoscopic nasal 
surgery, it can cost the patient thousands depending where the patient receives surgery.2  
Chronic sinusitis is responsible for 16 million outpatient visits a year.3 Therefore, it can 
be estimated that patients with symptomatic nasal polyps lead to 160,000-640,000 outpatient 
visits a year.3 This results in countless hours lost and work days missed.3 The diagnosis of nasal 
polyps is not always easy especially if they cannot be visualized on physical exam.3 Due to this, 
patients come back for more outpatient visits for recurrent symptoms.3 If a patient decides to 
undergo endoscopic sinus surgery to remove the nasal polyps, they could end up missing up to a 
week of work.3 
The exact cause or pathogenesis behind nasal polyps is unknown.4 However, most 
theories reveal they are caused by a reaction to allergies, inflammation, and rarely, cystic 
fibrosis.4 Nasal polyp formation usually takes place in the middle meatus.4 The meatus becomes 
edematous due to fluid collection which leads to a polypoidal change.4 This change develops the 
new sessile polyps.4 They become pedunculated and obstructive after excessive sneezing, 
rhinorrhea, and time, due to gravity.4 Nasal polyps present most commonly in patients with 
chronic rhinosinusitis but are also associated with other diseases such as asthma, aspirin-
exacerbated respiratory disease, cystic fibrosis, allergic fungal sinusitis, Kartagener’s syndrome, 
Young’s syndrome, eosinophilic granulomatosis with polyangiitis, and nasal mastocytosis.5 
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The methods used to treat nasal polyps are aimed at reducing the symptoms that they 
exacerbate or the underlying inflammation.6,7 For example, one of the most commonly used 
medications for treating the intranasal inflammation are topical nasal steroid sprays with 
triamcinolone, budesonide, or fluticasone.6,7 If the exacerbation is severe, oral corticosteroids 
may also be given such as oral prednisolone, methylprednisolone, or dexamethasone.6,7 To 
relieve any itching or rhinorrhea a medical provider could prescribe any antihistamine such as 
diphenhydramine, cetirizine, loratadine, or fexofenadine.6,7 To relieve symptoms such as sinus 
congestion, decongestants such as phenylephrine or pseudoephedrine can be prescribed.6,7 Some 
medical providers will prescribe cromolyn sodium for a patient with excessive inflammation for 
which intranasal steroid treatment failed or is contraindicated.6,7 Leukotriene inhibitors/modifiers 
such as Zafirlukast, Montelukast, or zileuton have recently become an adjuvant medication for 
nasal polyp associated symptoms, and are the medical therapy in question in this review.8 
Finally, if the symptoms are persistent and cannot be controlled, patients have an option to 
undergo endoscopic sinus surgery or polypectomy.8 
 Patients with nasal polyp obstruction have difficulty finding the right medications to 
continually treat their chronic symptoms. 9 Leukotriene inhibitors or modifiers are an adjunct 
medication option for patients with chronic sinusitis with nasal polyposis. 9 Leukotrienes act to 
sustain inflammatory reactions in the body such as asthma and allergies. 9 Leukotriene receptor 
antagonists such as Zafirlukast or Montelukast can bind to the receptors to block the 
inflammatory response leukotrienes perpetuate. 9 The blocked inflammatory response will reduce 
the symptoms identified as being problematic with nasal polyps.9 
OBJECTIVE  
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 The objective of this systematic review is to determine whether leukotriene 
inhibitors/modifiers reduce symptoms associated with nasal polyps. 
METHODS  
The three studies included in this review are all randomized control trials. 10-12 The 
studies were included because all patients were 18 years old or older, had been diagnosed with 
chronic rhinosinusitis with nasal polyposis, and were willing to participate in any imaging 
studies. 10-12 The studies were also included because they compared leukotriene inhibitors as 
adjunctive medical therapy versus a steroid based medical regimen that excluded leukotriene 
inhibitors.10-12 Patients excluded from these studies were ones who used oral/nasal steroid or 
immune-modulators in the past 4 weeks prior to the study. 10-12 Patients were also excluded if 
they had a history of acute infection, antrochoanal polyps, cystic fibrosis, fungal sinusitis, or 
gastroesophageal reflux disease. 10-12 Patients who had only unilateral polyps or history of 
sensitivity to protocol drug regimen were also excluded.10-12 Suri et al also excluded those with 
recent nasal surgery.12 
All three studies included symptom score reports proving significance to the patient 
population. 10-12 The articles were published in English, in peer-reviewed journals, and were 
investigated for inclusion in this review, by the author. Keywords for the PubMed and 
EBSCOhost search were “leukotriene”, “nasal polyp”, and “Montelukast”. 10-12 From that 
selection, the three articles included were chosen based on relevance to topic and outcomes 
which mattered to patients. 10-12 The three articles included were all published after 2014 and 
excluded patients under18 years old, patients with a contraindication to steroid intake, or patients 
with a sensitivity reaction to any of the medication regimen. 10-12 All statistics reported for the 
articles used p-value. 10-12 The demographic and characteristics are included below. 10-12 
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Table of demographics and characteristics of included studies (Table 1) 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Wu, 
(2016) 10 
 
 
RCT 31 25-62 Patients 
≥18 years 
old with the 
diagnosis of 
chronic 
sinusitis 
with NPs 
based on 
history, 
nasal 
endoscopy, 
and CT scan 
Patients who 
used oral/nasal 
steroid or 
immune-
modulators in the 
past 4 weeks 
prior to 
endoscopic 
surgery, had a 
history of acute 
infection, 
antrochoanal 
polyps, cystic 
fibrosis, fungal 
sinusitis, or 
gastroesophageal 
reflux disease  
0 Combined 
budesonide 
spray 
(Rhinocort 
Aqua) plus 
LTRA 
Montelukast 
(Singulair) 
10 mg once 
daily 
Yelverton, 
(2016)11 
RCT 27 18-76 Patients >17 
with chronic 
sinusitis 
with NPs 
who had no 
Montelukast 
therapy for 
at least 1 
month.  
Patients with 
cystic fibrosis, a 
fungal ball, or on 
a tapered 
prednisone 
regimen  
0 Post 
endoscopic 
sinus surgery 
regimen with 
added on 
Montelukast 
10mg 
Suri, 
(2015)12 
RCT 40 24-58 Patients 
who agreed 
to undergo 
an ENT 
examination 
and CT scan 
of paranasal 
sinuses, and 
nasal 
endoscopy 
Patients who had 
only unilateral 
polyps, current 
steroid intake, 
nasal surgery, or 
history of 
sensitivity to 
protocol drug 
regimen 
0 Oral steroid 
prednisolone 
35mg with 
nasal steroid 
budesonide 
(2 metered 
doses) with 
orally 
administered 
Montelukast 
10mg 
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OUTCOMES MEASURED  
The outcomes measured in these three studies were the improvement of symptoms post 
medication regimen. 10-12 Patients were asked to score their symptoms before and after the 
regimen.10-12 Each study used a different symptom score report. 10-12 These symptom score 
reports are Total Nasal Symptom Score (TNSS), Sino-Nasal Outcome Test (SNOT-20), and 
International Classification of Sinus Disease (ICSD). 10-12 Before the patients began treatment, 
intervention investigators also used the Lund-Kennedy Score System to determine polyp size, the 
Lund-Mackay to determine the polyp location, or endoscopy to determine the level of 
obstruction caused by the nasal polyps.10-12  
Wu et al used the Lund-Kennedy scoring system prior to treatment to determine polyp 
size before medical intervention. 10 Participants scored their current symptoms using the TNSS. 10 
This study then compared two groups, the control group, which received combined budesonide 
spray (hinocort aqua) alone and the experimental group which received combined budesonide 
spray (rhinocort aqua) plus Montelukast (singulair) 10 mg once daily. 10 After this intervention, 
the patients scored their symptoms using the TNSS. 10 The TNSS rates nasal congestion, runny 
nose, nasal itching, sneezing, or difficulty sleeping on a scale of none, mild, moderate, and 
severe. 10 The TNSS also rates the symptoms presence within 12 hours and within 2 weeks.10  
 Yelverton et al used the Lund-Kennedy and Lund-Mackay scoring systems to determine 
the size and location of the nasal polyps. 11 Before beginning the medical regimen, the patients 
scored their symptoms using SNOT-20. 11 The control group received a routine post endoscopic 
sinus surgery steroid based regimen while the experimental group used the same regimen with 
10mg on Montelukast as adjunct therapy. 11 They used the SNOT-20 patient symptom scoring 
system again to compare their course of intervention. 11 The SNOT-20 ranks sneezing, urge to 
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blow nose, runny nose, cough, post-nasal discharge, thick nasal discharge, ear fullness, dizziness, 
ear pain, facial pain/pressure, difficulty sleeping, fatigue, mood changes, and disruptions with 
work on a scale from very mild, mild, moderate, severe, to worst.11  
 Suri et all used endoscopy to determine the size and placement of the nasal polyps.12 
They gave the control group oral steroid prednisolone 35mg with nasal steroid budesonide (2 
metered doses).12 The experimental group was given the same regimen with additional orally 
administered Montelukast 10mg.12 They used ICSD before and after the intervention. 12 ICSD 
evaluates and rates patient’s symptoms of facial pain and pressure, headache, nasal blockage, 
congestion, nasal discharge, anosmia, and discomfort on a 0-10 scale, 10 being the worst.12 
RESULTS 
 In the study conducted by Wu et al, the TNSS symptom score total was used to determine 
the reduction of symptoms in the experimental group compared to the control group.10 The 
reduction was determined to be statistically significant.10 Before beginning their specific 
treatment regimens, the mean symptom score for the control group was 6.65 and the mean TNSS 
score the experimental group was 6.24.10 The mean change from baseline is greater for the 
experimental group treatment than for the control group (Table 2).10 This indicates the 
experimental group had overall less symptoms or a greater reduction in overall symptoms than 
the control group had after the medical intervention.10 The p-value result was determined to be 
statistically significant at p<0.01.10 The results from this randomized controlled trial are listed 
below in Table 2.10 
Table 2: Mean Change from Baseline, Wu et al10 
 TNSS Score Before 
Treatment 
TNSS Score After 
Treatment 
Mean Change from 
Baseline  
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Control Group 6.65* 5.8* -0.85 
Experimental 
Group 
6.24* 3.0* -3.24 
*p<0.01 
 In the study conducted by Yelverton et al, the SNOT-20 symptom score method showed 
the difference in results between the control group and the experimental group to be statistically 
significant.11 The participants were separated into groups after having completed the original 
questionnaire before the medical intervention.11 After the treatment regimen, the symptom score 
results for the experimental group were over four times better than the score for the control group 
(Table 3).11 The p-value was determined to be statically significant at <0.001 and the confidence 
interval as determined to be at 95%.11 The results are listed below in Table 3.11 
Table 3: Mean change from baseline, Yelverton et al11 
 SNOT-20 Score Before 
Treatment 
SNOT-20 Score After 
Treatment 
Mean Change from 
Baseline  
Control Group 29.53* 25.61* -3.92 
Experimental 
Group 
29.53* 13.25* -16.28 
*p<0.001 
 In the study conducted by Suri et al, the ICSD symptom score total was used to determine 
the reduction of symptoms in the experimental group compared to the control group as 
statistically significant.12 The groups were separated and asked to complete the questionnaire 
before and after the medical intervention.12 The questionnaire was filled out at 8 weeks and then 
again at 12 weeks.12 After 12 weeks, the total mean change from baseline was greater for the 
experimental group than for the control group.12 The p value for the 8 weeks mean change from 
baseline was 0.0006 and for 12 weeks it was 0.0034.12 The results are listed below in Table 4.12 
Table 4: Mean Change in Baseline, Suri et al12 
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 ICSD Score 
Before Treatment 
ICSD Score 
After Treatment- 
Week 8 
ICSD Score 
After Treatment- 
Week12 
Total Mean 
Change from 
Baseline  
Control Group 7.5* 5.2* 5.8* -1.7 
Experimental 
Group 
7.9* 4.1* 4.8* -3.1 
*p<0.05 
  
DISCUSSION 
 The three randomized controlled trials discussed in this review suggest that leukotriene 
inhibitors/modifiers are effective adjunctive therapy for the management of symptoms associated 
with nasal polyps.10-12 All three of these studies demonstrated statically significant reductions in 
their outcomes measured along with a statistical significance threshold set at p<0.05.10-12 
The randomized controlled trial by Suri et al recorded the symptom scores at 8 weeks and 
then again at 12 weeks.12 At 12 weeks the symptom score worsened overall but the score for the 
leukotriene inhibitor as adjunctive therapy remained lower than the score without the leukotriene 
inhibitor.12 This means that although the symptoms reappeared some on week 12, the addition of 
the leukotriene inhibitor, Montelukast, was still the more effective treatment.12 
It is also important to note that some of the participants in the study by Yelverton et al 
had endoscopic sinus surgery before participating in the randomized controlled trial.11 However, 
the patients were still considered patients in the category of chronic rhinosinusitis with nasal 
polyposis since they had received this diagnosis prior.11 The basis for using patients who had 
received endoscopic polyp removal surgery was that patients who experience nasal polyposis are 
at risk for having recurrent symptoms after their surgery.11 These patients are also at risk for 
having the polyps grow back because they have predisposition to them on a on a cellular level.11 
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The studies all showed statistically significant reduction of symptoms using leukotriene 
inhibitor/modifiers.10-12 However, there is some question as to whether additional therapy 
influences compliance. 10-12 The leukotriene inhibitor was an additional medication to the steroid 
therapy, so the experimental groups received twice as many medications as the control groups.10-
12  In these studies, although, compliance was not listed as an issue.10-12 
The Wu et al  and Suri et al included baseline location and size measurements but none 
followed up with the polyps after treatment. 10,11 In future studies, it would be beneficial to redo 
these measurements after the interventional treatment. This would have been valuable to this 
review as well, because the reduction in size of the polyps could have led to the decreased 
symptoms.  
These studies included very minimal reported data. All three RCTs used mean change 
from baseline and p values to determine the significance of Montelukast on the associated 
symptoms of nasal polyposis. 10-12 There should have been more information reported such as the 
decreased size of nasal polyps for example. The studies could have benefitted from reporting 
more information/ data results to make their claim that symptoms had been reduced greater in the 
experimental groups. The patient reporting was excellent regarding determining significant 
outcomes for patients. 10-12 However, more data to prove changes in the nasal mucosa or other 
ways to represent quality of life should have been used to verify the data provided by patient 
symptom scores. Lack of back up results makes the overall outcome of the review a weaker 
conclusion.  
CONCLUSION 
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 Leukotriene inhibitors/modifiers decrease the symptoms associated with nasal polyps. 
They are almost always given as an adjunctive medication instead of monotherapy. The steroid 
therapy which leukotriene inhibitors/modifiers are added to is effective at treating the symptoms 
alone. 10-12 However, symptoms decreased even more so with the addition of a leukotriene 
inhibitor/modifier. 10-12 Patients with nasal polyps will benefit from the addition of leukotriene 
inhibitors/modifiers to their medical regimen. 10-12 In the future, any trials planning to determine 
the effectiveness of medications on patients with nasal polyps could benefit from focusing solely 
on the reduction of size of the polyps. The reduction of polyp size would reduce obstruction and 
should theoretically reduce symptoms. There are still many discoveries to be made about the 
development of nasal polyps as well as the most effective away to handle the symptoms that they 
cause.  
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